Abstract
The functional role of the sodium iodide symporter (NIS) in extrathyroidal tissues was investigated by examining its mRNA and protein expression, together with the evidence of radioiodine (131I) uptake in 302 patients who underwent 131I total body scanning, following the administration of high doses of 131I for a papillary or follicular thyroid carcinoma. By using a real-time kinetic quantitative RT-PCR and immunohistochemistry, the expression of NIS protein was detected mainly in secretory tissues. In parallel, 131I uptake was evidenced in the majority of patients in the salivary glands (in 39%) and stomach (in 78%), but was found in breast in only 4 young female patients. These data demonstrate a strong correlation between the organ radioactivity distribution, as observed in vivo, and NIS protein expression. Interestingly, 131I is rarely concentrated by mammary glands, even when large doses are administered. Moreover, a 131I transfer in secretion fluids may represent a potential source of contamination responsible for false positive images and diagnostic pitfalls.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998, 338: 297–306.
Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999, 141: 443–56.
Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996, 379: 458–60.
Dohan O, De La Vieja A, Paroder V, et al. The Sodium/iodide symporter (NIS): characterization, regulation and medical significance. Endocr Rev 2003, 24:48–77.
Foley KP, Leonard MW, Engel JD. Quantification of RNA using the polymerase chain reaction. Trends Genet 1993, 9: 380–5.
Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. The sodium/iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001, 86: 3327–35.
Veronikis IE, Simkin P, Braverman LE. Thymic Uptake of Iodine—131 in the anterior mediastinum. J Nucl Med 1996, 37: 991–2.
Vermiglio F, Baudin E, Travagli JP, et al. Iodine concentration by the thymus in thyroid carcinoma. J Nucl Med 1996, 37: 1830–31.
Hammami MH, Bakheet S. Radioiodine breast uptake in non breast feeding women: Clinical and scintigraphic characteristics. J Nucl Med 1996, 37: 26–31.
Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid 1997, 7: 273–6.
Lacroix L, Mian C, Caillou B, et al. Na+/I- symporter and pendred syndrome gene and protein expressions in human extra-thyroidal tissues. Eur J Endocrinol 2001, 144: 297–302.
Caillou B, Troalen F, Baudin E, et al. Immunohistochemical detection of the Na+/I- symporter in human thyroid tissues. J Clin Endocrinol Metab 1998, 83: 4102–6.
Schlumberger M, Charbord P, Fragu P, et al. Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma. J Clin Endocrinol Metab 1983, 57: 148–51.
Jhiang SM, Cho JY, Ryu KY, et al. An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998, 139: 4416–9.
Vayre L, Sabourin JC, Caillou B, Ducreux M, Schlumberger M, Bidart JM. Immunohistochemical analysis of Na+/I-symporter distribution in human extrathyroidal tissues. Eur J Endocrinol 1999, 141: 382–6.
Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium/iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 1998, 83: 1746–51.
Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE. Analysis of human sodium/iodide sym-porter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 1999, 84: 4178–84.
Spitzweg C, Dutton CM, Castro MR, et al. Expression of the sodium iodide symporter in human kidney. Kidney Int 2001 59, 1013–23.
Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma. J Nucl Med 1984, 25: 755–8.
Van Nostrand D, Neutze J, Atkins F. Side effects of “rationale dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 1986, 27: 1519–27.
Bianchi R, Iervasi G, Matteuchi F, et al. Chromatographic identification in serum of endogenously radioiodinated thyroid hormones after iodine-131 whole-body scintigraphy in the follow-up of patients with differentiated thyroid carcinoma. J Nucl Med 1993, 34: 2032–7.
Davidson J, McDougall IR. How frequent is the thymus seen on whole-body iodine-131diagnostic and post-treatment scans? Eur J Nucl Med 2000, 27: 425–30.
Spitzweg C, Joba W, Heufelder AE. Expression of thyroid-related genes in human thymus. Thyroid 1999, 9: 133–41.
Tazebay UH, Wapnir RL, Levy O, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000, 6: 871–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bruno, R., Giannasio, P., Ronga, G. et al. Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest 27, 1010–1014 (2004). https://doi.org/10.1007/BF03345302
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345302